Prognostic role of EGR1 in breast cancer: A systematic review

Subbroto Kumar Saha, S. M. Riazul Islam, Tripti Saha, Afsana Nishat, Polash Kumar Biswas, Minchan Gil, Lewis Nkenyereye, Shaker El-Sappagh, Md Saiful Islam, Ssang Goo Cho

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

EGR1 (early growth response 1) is dysregulated in many cancers and exhibits both tumor suppressor and promoter activities, making it an appealing target for cancer therapy. Here, we used a systematic multi-omics analysis to review the expression of EGR1 and its role in regulating clinical outcomes in breast cancer (BC). EGR1 expression, its promoter methylation, and protein expression pattern were assessed using various publicly available tools. COSMIC-based somatic mutations and cBioPortal-based copy number alterations were analyzed, and the prognostic roles of EGR1 in BC were determined using Prognoscan and Kaplan-Meier Plotter. We also used bc-GenEx-Miner to investigate the EGR1 co-expression profile. EGR1 was more often downregulated in BC tissues than in normal breast tissue, and its knockdown was positively correlated with poor survival. Low EGR1 expression levels were also associated with increased risk of ER+, PR+, and HER2-BCs. High positive correlations were observed among EGR1, DUSP1, FOS, FOSB, CYR61, and JUN mRNA expression in BC tissue. This systematic review suggested that EGR1 expression may serve as a prognostic marker for BC patients and that clinicopathological parameters influence its prognostic utility. In addition to EGR1, DUSP1, FOS, FOSB, CYR61, and JUN can jointly be considered prognostic indicators for BC. [BMB Reports 2021; 54(10): 497-504]

Original languageEnglish
Pages (from-to)497-504
Number of pages8
JournalBMB Reports
Volume54
Issue number10
Early online date31 Oct 2021
DOIs
Publication statusPublished - 31 Oct 2021
Externally publishedYes

Cite this